Pandorum Technologies
Bioprinting pioneer creating lab-grown human tissues for drug discovery and regenerative medicine
- CEO / Founder
- Tuhin Bhowmick
- Team Size
- 51-200
- Stage
- Active
- Total Funding
- $50.5M
- Latest Round
- Series B
- Key Investors
- Protons Corporate, Ashish Kacholia, Indian Angel Network, 021 Capital, BTB Venture
Technology & Products
Key Products
Engineered liver models, corneal models, Kuragenx "Liquid Cornea" therapy, proprietary bioprinting platform
Technological Advantage
Proprietary bioprinting platform for high-precision tissue engineering
Differentiation
Value Proposition
Lab-grown human liver and corneal tissues for high-precision drug testing and regenerative medicine
How They Differentiate
Focus on Indian market and corneal blindness treatment
Market & Competition
Target Customers
Pharmaceutical companies, research institutions, hospitals
Industry Verticals
Pharmaceuticals, Biotechnology, Healthcare, Research
Competitors
Organovo, Aspect Biosystems, CELLINK
Growth & Milestones
Growth Metrics
Pre-revenue in FY24, ₹401Cr valuation, multiple pharmaceutical partnerships
Major Milestones
2011: Founded, 2016: Created India's first 3D printed liver tissue, 2024: $11M Pre-Series B, 2025: INR 85 Cr Series B led by Protons Corporate
Notable Customers
Pharmaceutical companies using liver/corneal models for drug testing